Recent Updates
Recently added Catalysts

Tagmokitug

Phase 1/2

Solid Tumor | Biologics | Oncology |Coherus Oncology, Inc.|Trials Updated: Nov 18, 2026

Tagmokitug development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment12

FDA Designations

No designations recorded

Tagmokitug clinical trials

Tagmokitug · 1 trial · 1 indication

Phase 1/2 1
NCT07945821A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid TumorsSolid Tumor
RECRUITING12 Analytics
PHASE1/PHASE2RECRUITING
A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Solid TumorUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Up to approximately 2.5 years
Number of Participants with Dose-limiting Toxicities (DLTs)
Up to 56 Days

Secondary Endpoints

mCRPC: Prostate Specific Antigen >=50% Response Rate (PSA50) per Prostate Cancer Working Group 3 (PCWG3) Criteria
Up to approximately 2.5 years
Objective Response Rate (ORR)
Up to approximately 2.5 years
Disease Control Rate (DCR)
Up to approximately 2.5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
mCRPC: Tagmokitug + PasritamigEXPERIMENTAL -

Interventions

NameTypeDescription
TagmokitugDRUGSpecified dose on specified days.
PasritamigDRUGSpecified dose on specified days.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites1

Key Inclusion Criteria: * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except f...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Solid Tumor")

Recent Changes (Last 90 Days)

LOWNov 18, 2026NCT07945821New Trial Detected: Recruiting